Description
Product Specifications
| Attribute | Details |
|---|---|
| Product Name | Dutasteride Soft Capsules |
| Generic Name | Dutasteride |
| CAS Number | 164656?23?9 magistralbr.caldic.com+15en.wikipedia.org+15sciencedirect.com+15accessdata.fda.gov |
| Molecular Formula | C??H??F?N?O? |
| Molecular Weight | ~528.5?g/mol |
| Dosage Form | Oral soft gelatin capsule |
| Strength | 0.5?mg per capsule |
| Pack Size | 10 capsules per box |
| Approval No. | China NMPA H20234210 |
| Product Code | 86901503000569 |
| Manufacturer | Jiangsu Wangao Pharmaceutical Co., Ltd. |
| Barcode | 6938033202990 |
| Storage Conditions | Store at 2–8?°C or 15–25?°C; protect from light |
| Intended Use | Laboratory/preclinical research only |
Mechanism of Action
Dutasteride is an irreversible inhibitor of both type I and II 5?-reductase enzymes, preventing conversion of testosterone to DHT. It reduces serum DHT levels by up to 98%, significantly more than finasteride (~65–70%) .
Research Applications & Pharmacology
Benign Prostatic Hyperplasia (BPH) Models: Widely used to study prostate volume reduction and LUTS in preclinical contexts .
Androgenetic Alopecia (AGA) Models: More effective than finasteride in hair growth studies, especially at 0.5?mg dosing .
Pharmacokinetics: Oral bioavailability ~60%, protein binding ~99%, metabolized via CYP3A4, elimination half-life ~4–5 weeks, mainly excreted in feces (~40%) .
Research Formulation Impact: Soft gelatin capsules offer higher bioavailability than tablets or hard capsules .
Safety Profile & Handling
Adverse Effects: Can cause sexual dysfunction, breast tenderness/gynecomastia (~1.3%), depression, and self-harm risks in long-term or high-dose models.
Drug Interactions/Contraindications: Avoid use in models with CYP3A4 inhibitors; contraindicated in female and pregnant subjects due to teratogenic risk .
Handling Instructions: Wear lab-safe PPE. Store per label instructions. Dispose of per institutional safety protocols.


Reviews
There are no reviews yet.